Skip to main content

ORIGINAL RESEARCH article

Front. Gastroenterol.
Sec. Therapy in Gastroenterology
Volume 3 - 2024 | doi: 10.3389/fgstr.2024.1489876

Prevalence and Characteristics of Gastrointestinal Disorders, Medication Use, and Diagnostic Interventions in Pediatric Patients with Cystic Fibrosis: A Nested Case-Control Analysis from the TriNetX EMR-Derived Global Research Network Real-World Dataset

Provisionally accepted
Carolena Trocchia Carolena Trocchia 1,2*Maua Mosha Maua Mosha 3Bailey Hamner Bailey Hamner 4Neil Goldenberg Neil Goldenberg 3Racha Khalaf Racha Khalaf 4
  • 1 School of Medicine, Stanford University, Stanford, United States
  • 2 Stanford Healthcare, Stanford, California, United States
  • 3 Johns Hopkins All Children's Hospital, Saint Petersburg, Florida, United States
  • 4 University of South Florida, Tampa, Florida, United States

The final, formatted version of the article will be published soon.

    The aim of this study was to describe, among pediatric patients with CF (PwCF) compared to a large cohort of healthy controls, the prevalence, and types of 1) GI disorders; 2) GI medication use; and 3) GI procedural interventions. This was a multicenter case-control analysis using the TriNetX electronic medical record (EMR) platform that included patients with an ICD9/10 diagnosis code between the age of zero to ≤ 21 years between January 1 st , 2010, and January 1 st , 2020. In pediatric PwCF compared to those without CF, the prevalence of any GI disorder (73% versus <1%), diseases of the biliary tract and pancreas (43% vs. <1%; p<.0001), hepatic disease (8.8% vs. <1%; p<.0001), and intestinal disease (43% vs. <1%; p<.0001) were each significantly greater in PwCF (p<0.0001). The prevalence of GI diagnoses, use of GI medications, and frequency of GI procedures are all higher among pediatric PwCF, however given the high prevalence of disease, the rate of procedures is proportionally low.• Numerous gastrointestinal (GI) disorders have been associated with CF• Prior studies have shown there is a high GI symptom burden• There is a greater prevalence of GI disease and GI medications in PwCF than controls• There is a lower prevalence of GI procedures in this population despite the high burden of disease, though still substantially greater when compared to controls.• There is a need for further focus on these disorders in the new era of HEMT

    Keywords: Cystic Fibrosis, Exocrine Pancreatic Insufficiency, elexacaftor/tezacaftor/ivacaftor (ETI), modulator therapy, gastrointestinal disease

    Received: 04 Sep 2024; Accepted: 05 Dec 2024.

    Copyright: © 2024 Trocchia, Mosha, Hamner, Goldenberg and Khalaf. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Carolena Trocchia, School of Medicine, Stanford University, Stanford, United States

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.